Skip to main content

Specialty Pharmacy

  • Amgen drug reduces risk of prostate cancer spreading to bones, study finds

    THOUSAND OAKS, Calif. — A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.

  • FDA revokes breast cancer approval for Avastin

    SILVER SPRING, Md. — A drug widely used to treat breast cancer is not safe or effective, the Food and Drug Administration said Friday.

  • FDA approves Erwinaze for acute lymphoblastic leukemia

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new chemotherapy drug for treating acute lymphoblastic leukemia, the agency said Friday.

    The FDA announced the approval of EUSA Pharma's Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with ALL who have developed an allergy to E. coli-derived asparaginase and pegaspargase chemotherapy drugs.

  • Need for more convenient therapies, competition from generics, biosimilars spurs RA drug development

    MOUNTAIN VIEW, Calif. — The increase in the number of people with rheumatoid arthritis, and the challenges posed to drug makers by generics, is encouraging the development of new drugs for the disease, according to a new report by Frost & Sullivan.

  • Former Mercer executive named president of CVS Caremark's Accordant business

    WOONSOCKET, R.I. — CVS Caremark has appointed Kevin Murphy president for Accordant Health Services, a CVS Caremark company that provides disease management and case management services for people with rare chronic conditions.

    Murphy is in charge of integrating the company's leading rare disease management programs with its specialty pharmacy programs and new focus on medical pharmacy management.

  • FDA approves drug for rare bone marrow disorder

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a rare bone marrow disease, the agency said Wednesday.

  • Walgreens general counsel named to Unigene board

    BOONTON, N.J. — Unigene Labs, a developer of peptide-based therapeutics, on Wednesday appointed Walgreens' Thomas Sabatino Jr. to its board of directors.

    "[Sabatino's] extensive industry experience and impressive track record — specifically, his knowledge of the legal and regulatory landscape for pharmaceutical companies — will be invaluable as Unigene continues to execute against its business transformation," Unigene chairman Richard Levy said.

  • Genzyme announces phase-3 results of Lemtrada in patients with relapsing MS

    CAMBRIDGE, Mass. — A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

    Genzyme, acquired earlier this year by French drug maker Sanofi, announced results of the phase-3 "CARE-MS II" trial of Lemtrada (alemtuzumab), saying the drug "significantly reduced" worsening of disability and relapse in patients with MS, compared with Rebif (interferon beta-1a), made by Pfizer and German drug maker Merck KGaA, a separate company from U.S.-based Merck.

X
This ad will auto-close in 10 seconds